Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2015, Article ID 627631, 9 pages
Research Article

Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

1Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
2Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA
3Optum, 950 Winter Street, Suite 2800, Waltham, MA 02451, USA
4Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA

Received 3 September 2015; Accepted 3 November 2015

Academic Editor: Salvatore Minisola

Copyright © 2015 Stuart Silverman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

The supplementary material provides two tables with additional detail on model estimation. The first table provides 6-month discontinuation rates for all treatments, up to three years. The second table provides the relative risks of mortality for each fracture type, compared to the general population.

  1. Supplementary Material